Novartis said on Monday it received regulatory clearance to open a separate trading line for potentially up to 16.5 billion Swiss francs ($18.1 billion) in stock repurchases even as its ongoing $15 billion buyback programme is close to completion.
At last week’s annual shareholder meeting, the company won investor authorization for up to 10 billion francs in buybacks, which comes on top of 6.5 billion francs in prior authorizations.
A company spokesperson told Reuters on Monday that the “majority” of its ongoing $15 billion buyback programme was already completed, adding that any repurchases would be decided by the board of directors.
She declined to comment on specific amounts.
Novartis laid out plans for the $15 billion programme in late 2021, after receiving $20.7 billion for the sale of its nearly one-third voting stake in Roche back to its cross-town rival.
The spokesperson said the remainder of that repurchase programme would be carried out while allowing for “bolt-on M&A, whilst providing a strong, growing dividend and reinvesting in the business”.
Novartis’s CEO Vas Narasimhan said in January that the group was looking at the “full range of M&A opportunities”, but the focus was on assets worth no more than $5 billion.
Source : Reuters
Frontier innovation may start at home, but new technologies tend to spread across borders through…
Do banks fail because of runs or because they become insolvent? Answering this question is…
The US college wage premium nearly doubled between 1980 and 2010, rising fastest in dense…
Europe’s rising external surplus now rivals China’s, reflecting weak investment and growing surpluses, pointing to…
The 2025 Sevilla Commitment renews the push for domestic revenue mobilisation, with the EU needing…
This essay analyses the causes of, and remedies for, external imbalances, and what countries should…